press release Sept. 18, 2012, 6:15 a.m. EDT
Provectus Pharmaceuticals to Present Data on PV-10 at the Society for Immunotherapy of Cancer Annual Meeting on October 26 and 27, 2012
KNOXVILLE, Tenn., Sep 18, 2012 (BUSINESS WIRE) -- Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, pvct.com ), a development-stage oncology and dermatology biopharmaceutical company, announces that nonclinical [compassionate use?] data on PV-10 will be presented at the Society for Immunotherapy of Cancer Annual Meeting on October 26 and 27, 2012 in North Bethesda, MD. Dr. Craig Dees, PhD, CEO of Provectus, will be presenting nonclinical [compassionate use?] PV-10 data that have been included in Abstract #1452582, in a poster presentation (Poster #169) entitled "Generation of an antitumor response and immunity using a small molecule drug (PV-10)." PV-10 is Provectus Pharmaceuticals's novel oncology drug designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects.
Dr. Dees said, "We are pleased to have been accepted by SITC and are looking forward to presenting data from nonclinical research conducted on PV-10."
About the SITC 27th Annual Meeting
The SITC 27th Annual Meeting provides a multidisciplinary educational environment composed of cutting-edge research, informative oral presentations, poster presentations and valuable networking opportunities unique to SITC. Understanding of tumor immunobiology has increased dramatically in recent years, leading to the successful development of new immune-based treatment options to improve cancer outcomes. The SITC Primer on Tumor Immunology and Cancer Immunotherapy is designed to provide a foundation for understanding core immunology principles as they related to basic and clinical research in immunotherapy of cancer. Prominent investigators will summarize central themes and recent research in tumor immunology and cancer immunotherapy including innate immunity, dendritic cells, T cell differentiation, antibody therapy, and the tumor microenvironment as well as recent advances in the clinical application of cancer vaccines, coinhibition and costimulation of immune cells for immunotherapy, adoptive immunotherapy, and immune monitoring in clinical trials of cancer immunotherapies. These topics will be addressed in a series of lectures by thought leaders in the field and through interactive questions and answer discussions. |
